Viatris Inc. to Participate in Barclays Global Healthcare Conference
03/04/2021 - 11:37 AM
PITTSBURGH , March 4, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday March 10, 2021 . CEO Michael Goettler , President Rajiv Malik and Chief Financial Officer Sanjeev Narula will answer questions about the company at 3:00 p.m. ET .
Interested parties can access a live webcast of the event at investor.viatris.com . An archived version also will be available following the live event and can be accessed at the same location for a limited time.
About Viatris ® . Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad , India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc , LinkedIn and YouTube .
http://www.prnewswire.com/news-releases/viatris-inc-to-participate-in-barclays-global-healthcare-conference-301240835.html
SOURCE Viatris Inc.
VTRS Rankings
#2929 Ranked by Stock Gains
VTRS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major
About VTRS
mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.
